{"id":"coordinated-bolus","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL3833410","moleculeType":"Small molecule","molecularWeight":"222.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This appears to be a therapeutic approach or clinical protocol rather than a discrete pharmaceutical agent. It involves coordinated timing of insulin bolus administration, likely in the context of insulin pump therapy or diabetes management, to better match meal intake and glucose dynamics. The mechanism focuses on improving glycemic control through optimized insulin dosing coordination.","oneSentence":"Coordinated bolus is a clinical protocol for synchronized insulin delivery designed to optimize postprandial glucose control.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:23:49.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus (insulin-dependent glucose management)"}]},"trialDetails":[{"nctId":"NCT05591040","phase":"NA","title":"Biofeedback as an Adjunctive Treatment for Post-stroke Dysphagia","status":"RECRUITING","sponsor":"IRCCS San Camillo, Venezia, Italy","startDate":"2022-10-30","conditions":"Dysphagia, Rehabilitation, Stroke","enrollment":100},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":"Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8","enrollment":24},{"nctId":"NCT02359968","phase":"PHASE2","title":"PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-02-26","conditions":"Esophageal Neoplasms, Gastro-esophageal Junction Cancer","enrollment":106},{"nctId":"NCT07474727","phase":"PHASE2","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2026-04-01","conditions":"Colorectal Cancer","enrollment":180},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":"Colorectal Neoplasms","enrollment":400},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT06860802","phase":"PHASE1","title":"Precision Antibiotic Dosing for Appendectomy","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-02-28","conditions":"Appendicitis (Diagnosis)","enrollment":46},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":"Colorectal Cancer","enrollment":528},{"nctId":"NCT04757363","phase":"PHASE2","title":"A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-11","conditions":"Esophagogastric Cancer, HER2-Negative","enrollment":39},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT07446465","phase":"PHASE4","title":"FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ye Xu","startDate":"2026-03-01","conditions":"Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)","enrollment":42},{"nctId":"NCT07437287","phase":"PHASE2, PHASE3","title":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-07","conditions":"Biliary Tract Cancer (BTC)","enrollment":160},{"nctId":"NCT04430738","phase":"PHASE2","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-09-15","conditions":"Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma","enrollment":40},{"nctId":"NCT03388190","phase":"PHASE2","title":"METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin","status":"COMPLETED","sponsor":"University Hospital, Akershus","startDate":"2018-05-29","conditions":"Colorectal Cancer Metastatic","enrollment":80},{"nctId":"NCT03504397","phase":"PHASE3","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-21","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":565},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT06268015","phase":"PHASE2","title":"Botensilimab and Balstilimab Optimization in Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicholas DeVito, MD","startDate":"2024-11-18","conditions":"Colorectal Cancer","enrollment":16},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT02912559","phase":"PHASE3","title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-16","conditions":"Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome","enrollment":712},{"nctId":"NCT07353827","phase":"PHASE2","title":"FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy","enrollment":36},{"nctId":"NCT07056777","phase":"PHASE1, PHASE2","title":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Zhejiang Doer Biologics Co., Ltd.","startDate":"2025-03-25","conditions":"Gastrointestinal Cancer","enrollment":186},{"nctId":"NCT03977233","phase":"PHASE2","title":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT06205485","phase":"PHASE3","title":"Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-06-26","conditions":"Rectal Cancer","enrollment":250},{"nctId":"NCT07334587","phase":"NA","title":"Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Allama Iqbal Medical College","startDate":"2025-09-01","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":248},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT05993481","phase":"NA","title":"The Noninvasive Blood Pressure Measurement Effect on the Hypotension","status":"ENROLLING_BY_INVITATION","sponsor":"Konya City Hospital","startDate":"2024-10-25","conditions":"Hypotension During Surgery","enrollment":640},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT04949256","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-28","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":864},{"nctId":"NCT05008809","phase":"PHASE3","title":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-06","conditions":"Colorectal Cancer","enrollment":507},{"nctId":"NCT06846346","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-20","conditions":"Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma","enrollment":88},{"nctId":"NCT04662710","phase":"PHASE3","title":"Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-30","conditions":"Advanced/Metastatic Gastroesophageal Adenocarcinoma","enrollment":895},{"nctId":"NCT06841679","phase":"PHASE2, PHASE3","title":"Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":778},{"nctId":"NCT06783491","phase":"PHASE3","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-12-31","conditions":"Locally Advanced Colorectal Cancer","enrollment":1083},{"nctId":"NCT06328738","phase":"PHASE1","title":"ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2024-05-30","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors","enrollment":275},{"nctId":"NCT01489865","phase":"PHASE1, PHASE2","title":"ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2011-01-03","conditions":"Metastatic Pancreatic Cancer","enrollment":64},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03505320","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-29","conditions":"Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer","enrollment":143},{"nctId":"NCT06790706","phase":"PHASE2","title":"IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-10-01","conditions":"Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma","enrollment":154},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT06253611","phase":"PHASE2","title":"First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2024-04-16","conditions":"Gastric Cancer","enrollment":120},{"nctId":"NCT03110926","phase":"PHASE2","title":"Induction Chemotherapy for Locally Advanced Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2017-06-19","conditions":"Esophageal Carcinoma","enrollment":40},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT07118800","phase":"PHASE3","title":"Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-12-15","conditions":"Locally Advanced Rectal Adenocarcinoma","enrollment":160},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT06441565","phase":"PHASE2, PHASE3","title":"Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-24","conditions":"Colorectal Cancer","enrollment":84},{"nctId":"NCT04900623","phase":"PHASE2","title":"Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study","status":"RECRUITING","sponsor":"Jonathan Schoenfeld, MD, MPH","startDate":"2021-07-02","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage","enrollment":145},{"nctId":"NCT05571644","phase":"PHASE2","title":"Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-10","conditions":"Colorectal Cancer","enrollment":143},{"nctId":"NCT02885753","phase":"PHASE3","title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-12","conditions":"Colorectal Neoplasms","enrollment":348},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT00873275","phase":"PHASE1","title":"Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2009-03-11","conditions":"Colorectal Cancer","enrollment":11},{"nctId":"NCT07025174","phase":"PHASE2","title":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT06280495","phase":"PHASE2, PHASE3","title":"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-02-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":156},{"nctId":"NCT04861558","phase":"PHASE3","title":"Efficacy of Hyperthermic Intraperitoneal Chemotherapy","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2021-05-01","conditions":"Colorectal Cancer, Peritoneal Metastases","enrollment":213},{"nctId":"NCT06988852","phase":"PHASE2","title":"FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-05-01","conditions":"Colorectal Liver Metastasis (CRLM)","enrollment":300},{"nctId":"NCT06741020","phase":"PHASE1, PHASE2","title":"Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":10},{"nctId":"NCT05624138","phase":"PHASE3","title":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2022-11-09","conditions":"Neuropathy;Peripheral","enrollment":64},{"nctId":"NCT02394834","phase":"","title":"An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":757},{"nctId":"NCT04068103","phase":"PHASE2, PHASE3","title":"Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2019-12-16","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8","enrollment":635},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT04251715","phase":"PHASE2","title":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-04-28","conditions":"Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":5},{"nctId":"NCT06928584","phase":"PHASE2","title":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-10","conditions":"Locally Recurrent Rectal Cancer","enrollment":221},{"nctId":"NCT06860477","phase":"PHASE2","title":"Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-18","conditions":"Intrahepatic Cholangiocellular Carcinoma","enrollment":92},{"nctId":"NCT06899477","phase":"PHASE3","title":"Pre-Operative Treatment in REseCTable COlon CanceR","status":"NOT_YET_RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2025-04","conditions":"Colo-rectal Cancer, Colon Cancer, Colon Carcinoma","enrollment":714},{"nctId":"NCT02572141","phase":"PHASE3","title":"FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2015-01-01","conditions":"Colon Cancer","enrollment":738},{"nctId":"NCT03006432","phase":"PHASE3","title":"PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-12-19","conditions":"OESOPHAGO-GASTRIC CARCINOMA","enrollment":507},{"nctId":"NCT02980510","phase":"PHASE2","title":"Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2016-12","conditions":"Metastatic Colorectal Cancer","enrollment":219},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT01652196","phase":"PHASE2","title":"Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer","status":"COMPLETED","sponsor":"John Hays","startDate":"2012-11-14","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon","enrollment":56},{"nctId":"NCT03699319","phase":"PHASE1, PHASE2","title":"CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"David Bajor, MD","startDate":"2018-12-07","conditions":"Pancreatic Cancer","enrollment":49},{"nctId":"NCT05859750","phase":"PHASE2","title":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-05-25","conditions":"Pancreatic Cancer","enrollment":78},{"nctId":"NCT06094140","phase":"PHASE2","title":"NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2022-05-20","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT02455245","phase":"PHASE3","title":"A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alicia Lenzen","startDate":"2015-03","conditions":"Low Grade Glioma","enrollment":95},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT03678883","phase":"PHASE2","title":"9-ING-41 in Patients with Advanced Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actuate Therapeutics Inc.","startDate":"2019-01-04","conditions":"Cancer, Pancreatic Cancer, Sarcoma","enrollment":350},{"nctId":"NCT05476796","phase":"PHASE2","title":"Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-06-23","conditions":"Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":118},{"nctId":"NCT00807911","phase":"PHASE2","title":"Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-11-01","conditions":"Rectal Cancer","enrollment":322},{"nctId":"NCT03164655","phase":"PHASE2","title":"Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-07-25","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT05960227","phase":"PHASE2","title":"Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2023-01-06","conditions":"Anemia, Iron Deficiency, Acute Kidney Injury","enrollment":120},{"nctId":"NCT04488159","phase":"PHASE3","title":"Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer","status":"WITHDRAWN","sponsor":"Johannes Laengle, MD, PhD","startDate":"2024-12-01","conditions":"Colon Cancer Stage III","enrollment":""},{"nctId":"NCT05325658","phase":"","title":"Influence of Modified Diet, Exercise and Electrical Swallowing Muscle Stimulation on Swallowing Function and Quality of Life in Elderly Patients With Oropharyngeal Dysphagia","status":"COMPLETED","sponsor":"Lithuanian University of Health Sciences","startDate":"2021-05-21","conditions":"Oropharyngeal Dysphagia","enrollment":64},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT03300544","phase":"PHASE1","title":"Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-14","conditions":"Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma","enrollment":3},{"nctId":"NCT06409637","phase":"PHASE1, PHASE2","title":"FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-01-01","conditions":"Liver Cancer, Liver Transplant","enrollment":62},{"nctId":"NCT00321828","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-03","conditions":"Colorectal Cancer","enrollment":90},{"nctId":"NCT05112536","phase":"PHASE2","title":"Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2022-03-03","conditions":"Triple Negative Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT03698461","phase":"PHASE2","title":"Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2019-05-15","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms","enrollment":20},{"nctId":"NCT03783936","phase":"PHASE2","title":"Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas","status":"COMPLETED","sponsor":"Ashwin Somasundaram","startDate":"2019-01-24","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":430,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Coordinated bolus","genericName":"Coordinated bolus","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Coordinated bolus is a clinical protocol for synchronized insulin delivery designed to optimize postprandial glucose control. Used for Type 1 diabetes mellitus (insulin-dependent glucose management).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}